Cargando…

Treatment paradigm and prognostic factor analyses of rectal squamous cell carcinoma

BACKGROUND: Rectal squamous cell carcinoma (rSCC) is a rare pathological subtype of rectal cancer. There is no consensus on the treatment paradigm for patients with rSCC. This study aimed to provide a paradigm for clinical treatment and develop a prognostic nomogram. METHODS: Patients diagnosed with...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Rui, Zhang, Jiahui, Zhang, Yinjie, Yan, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243597/
https://www.ncbi.nlm.nih.gov/pubmed/37287925
http://dx.doi.org/10.3389/fonc.2023.1160159
_version_ 1785054455421468672
author Liu, Rui
Zhang, Jiahui
Zhang, Yinjie
Yan, Jin
author_facet Liu, Rui
Zhang, Jiahui
Zhang, Yinjie
Yan, Jin
author_sort Liu, Rui
collection PubMed
description BACKGROUND: Rectal squamous cell carcinoma (rSCC) is a rare pathological subtype of rectal cancer. There is no consensus on the treatment paradigm for patients with rSCC. This study aimed to provide a paradigm for clinical treatment and develop a prognostic nomogram. METHODS: Patients diagnosed with rSCC between 2010 and 2019 were identified in the Surveillance, Epidemiology, and End Results (SEER) database. According to the TNM staging system, Kaplan−Meier (K-M) survival analysis was used to identify the survival benefits of different treatments in patients with rSCC. The Cox regression method was used to identify independent prognostic risk factors. Nomograms were evaluated by Harrell’s concordance index (C-index), calibration curves, decision curve analysis (DCA) and K-M curves. RESULTS: Data for 463 patients with rSCC were extracted from the SEER database. Survival analysis showed that there was no significant difference in median cancer-specific survival (CSS) among patients with TNM stage 1 rSCC treated with radiotherapy (RT), chemoradiotherapy (CRT) or surgery (P = 0.285). In TNM stage 2 patients, there was a significant difference in median CSS among those treated with surgery (49.5 months), RT (24 months), and CRT (63 months) (P = 0.003). In TNM stage 3 patients, there was a significant difference in median CSS among those treated with CRT (58 months), CRT plus surgery (56 months) and no treatment (9.5 months) (P < 0.001). In TNM stage 4 patients, there was no significant difference in median CSS among those treated with CRT, chemotherapy (CT), CRT plus surgery and no treatment (P = 0.122). Cox regression analysis showed that age, marital status, T stage, N stage, M stage, PNI, tumor size, RT, CT, and surgery were independent risk factors for CSS. The 1-, 3-, and 5-year C-indexes were 0.877, 0.781, and 0.767, respectively. The calibration curve showed that the model had excellent calibration. The DCA curve showed that the model had excellent clinical application value. CONCLUSION: RT or surgery is recommended for patients with stage 1 rSCC, and CRT is recommended for patients with stage 2, and stage 3 rSCC. Age, marital status, T stage, N stage, M stage, PNI, tumor size, RT, CT, and surgery are independent risk factors for CSS in patients with rSCC. The model based on the above independent risk factors has excellent prediction efficiency.
format Online
Article
Text
id pubmed-10243597
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102435972023-06-07 Treatment paradigm and prognostic factor analyses of rectal squamous cell carcinoma Liu, Rui Zhang, Jiahui Zhang, Yinjie Yan, Jin Front Oncol Oncology BACKGROUND: Rectal squamous cell carcinoma (rSCC) is a rare pathological subtype of rectal cancer. There is no consensus on the treatment paradigm for patients with rSCC. This study aimed to provide a paradigm for clinical treatment and develop a prognostic nomogram. METHODS: Patients diagnosed with rSCC between 2010 and 2019 were identified in the Surveillance, Epidemiology, and End Results (SEER) database. According to the TNM staging system, Kaplan−Meier (K-M) survival analysis was used to identify the survival benefits of different treatments in patients with rSCC. The Cox regression method was used to identify independent prognostic risk factors. Nomograms were evaluated by Harrell’s concordance index (C-index), calibration curves, decision curve analysis (DCA) and K-M curves. RESULTS: Data for 463 patients with rSCC were extracted from the SEER database. Survival analysis showed that there was no significant difference in median cancer-specific survival (CSS) among patients with TNM stage 1 rSCC treated with radiotherapy (RT), chemoradiotherapy (CRT) or surgery (P = 0.285). In TNM stage 2 patients, there was a significant difference in median CSS among those treated with surgery (49.5 months), RT (24 months), and CRT (63 months) (P = 0.003). In TNM stage 3 patients, there was a significant difference in median CSS among those treated with CRT (58 months), CRT plus surgery (56 months) and no treatment (9.5 months) (P < 0.001). In TNM stage 4 patients, there was no significant difference in median CSS among those treated with CRT, chemotherapy (CT), CRT plus surgery and no treatment (P = 0.122). Cox regression analysis showed that age, marital status, T stage, N stage, M stage, PNI, tumor size, RT, CT, and surgery were independent risk factors for CSS. The 1-, 3-, and 5-year C-indexes were 0.877, 0.781, and 0.767, respectively. The calibration curve showed that the model had excellent calibration. The DCA curve showed that the model had excellent clinical application value. CONCLUSION: RT or surgery is recommended for patients with stage 1 rSCC, and CRT is recommended for patients with stage 2, and stage 3 rSCC. Age, marital status, T stage, N stage, M stage, PNI, tumor size, RT, CT, and surgery are independent risk factors for CSS in patients with rSCC. The model based on the above independent risk factors has excellent prediction efficiency. Frontiers Media S.A. 2023-05-23 /pmc/articles/PMC10243597/ /pubmed/37287925 http://dx.doi.org/10.3389/fonc.2023.1160159 Text en Copyright © 2023 Liu, Zhang, Zhang and Yan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Rui
Zhang, Jiahui
Zhang, Yinjie
Yan, Jin
Treatment paradigm and prognostic factor analyses of rectal squamous cell carcinoma
title Treatment paradigm and prognostic factor analyses of rectal squamous cell carcinoma
title_full Treatment paradigm and prognostic factor analyses of rectal squamous cell carcinoma
title_fullStr Treatment paradigm and prognostic factor analyses of rectal squamous cell carcinoma
title_full_unstemmed Treatment paradigm and prognostic factor analyses of rectal squamous cell carcinoma
title_short Treatment paradigm and prognostic factor analyses of rectal squamous cell carcinoma
title_sort treatment paradigm and prognostic factor analyses of rectal squamous cell carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243597/
https://www.ncbi.nlm.nih.gov/pubmed/37287925
http://dx.doi.org/10.3389/fonc.2023.1160159
work_keys_str_mv AT liurui treatmentparadigmandprognosticfactoranalysesofrectalsquamouscellcarcinoma
AT zhangjiahui treatmentparadigmandprognosticfactoranalysesofrectalsquamouscellcarcinoma
AT zhangyinjie treatmentparadigmandprognosticfactoranalysesofrectalsquamouscellcarcinoma
AT yanjin treatmentparadigmandprognosticfactoranalysesofrectalsquamouscellcarcinoma